Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone

0142374 - FGU-C 20020105 RIV US eng J - Článek v odborném periodiku
Qi, N. - Kazdová, L. - Zídek, Václav - Landa, Vladimír - Křen, Vladimír - Pershadsingh, H. A. - St.Lezin, E. - Abumrad, N. A. - Pravenec, Michal - Kurtz, W. T.
Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone.
Journal of Biological Chemistry. Roč. 277, č. 50 (2002), s. 48501-48507. ISSN 0021-9258. E-ISSN 1083-351X
Grant CEP: GA ČR GA301/00/1636; GA ČR GV204/98/K015; GA MŠMT LN00A079
Grant ostatní: HHMI(US) 55000331
Výzkumný záměr: CEZ:AV0Z5011922
Klíčová slova: thiazolidinedione * Cd36 * transgenic SHR
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 6.696, rok: 2002

295 To specifically investigate the role of the Cd36 fatty acid transporter gene in the insulin sensitizing actions of thiazolidinediones, we studied the metabolic effects of pioglitazone in spontaneously hypertensive rats (SHR) that harbor a deletion mutation in Cd36 in comparison to congenic and transgenic strains of SHR that express wild type Cd36. Our findings provide direct pharmacogenetic evidence that in the SHR model, Cd36 is a key determinant of the insulin sensitizing actions of a thiazolidinedione ligand of PPAR?.
Trvalý link: http://hdl.handle.net/11104/0040080